Be part of the knowledge.™

Endocrinology

117

LikeLikedUnlike

Episodes 16-30 of 52

MOA Deep Dive: The MRA Spectrum
MinuteCE®
MOA Deep Dive: The MRA Spectrum
- John McMurray, MD
  Peer
- Hiddo L. Heerspink, PhD
  Peer
1.25 program credits
Nonsteroidal MRAs: The CKD/T1D Potential
MinuteCE®
Nonsteroidal MRAs: The CKD/T1D Potential
- John McMurray, MD
  Peer
- Hiddo L. Heerspink, PhD
  Peer
1.25 program credits
Nonsteroidal MRAs: The CKD/T2D Advantage
MinuteCE®
Nonsteroidal MRAs: The CKD/T2D Advantage
- John McMurray, MD
  Peer
- Pardeep Jhund, MD, PhD
  Peer
1.25 program credits
MinuteCE®
Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care
- Pardeep Jhund, MD, PhD
  Peer
- Hiddo L. Heerspink, PhD
  Peer
- John McMurray, MD
  Peer
- Akshay S. Desai, MD
  Peer
- Csaba P. Kovesdy, MD
  Peer
- Finnian R. Mc Causland, MD
  Peer
- Orly Vardeny, MD
  Peer
- Muthiah Vaduganathan, MD, MPH
  Peer
1.25 credits 10 episodes
KOL KNOCKOUT™: Endocrinology Edition – Challenging Cases of Thyroid Eye Disease
CME/CE
KOL KNOCKOUT™: Endocrinology Edition – Challenging Cases of Thyroid Eye Disease
- Malini Gupta, MD, ECNU, FACE
  Peer
- Kaniksha Desai, MD, ECNU, FACE
  Peer
- Alireza Falahati, MD, FACE
  Peer
- Sonalika Khachikian, MD
  Peer
- Anupam Kotwal, MD, MSc, FACE, FRCP (Edin)
  Peer
- John Woody Sistrunk, MD
  Peer
- Rokshana R. Thanadar, MD, FACE, FEAA
  Peer
- Melissa Garduno Young, MD, FACE, FACP, ECNU
  Peer
1.50 credits
A Multidisciplinary Exploration of Complexities and Controversies in Thyroid Eye Disease: Spotlight on Diagnosis
CME/CE
A Multidisciplinary Exploration of Complexities and Controversies in Thyroid Eye Disease: Spotlight on Diagnosis
- Prem S. Subramanian, MD, PhD
  Peer
- Raymond Cho, MD, FACS
  Peer
- Sonalika Khachikian, MD
  Peer
- Christian Nasr, MD
  Peer
- Lisa M. Nijm, MD, JD
  Peer
- Madhura Tamhankar, MD
  Peer
1.00 credits
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
MinuteCE®
Clinical Practice Guidelines for Hyperlipidemia: What Are the Recommendations?
- David J. Maron, MD
  Peer
0.75 program credits
MACE and SGLT2 Inhibitors: Do They Have an Impact?
MinuteCE®
MACE and SGLT2 Inhibitors: Do They Have an Impact?
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
0.75 program credits
TRANSFORM Trial: Overview and Potential Implications 
MinuteCE®
TRANSFORM Trial: Overview and Potential Implications 
- Pam R. Taub, MD, FACC, FASPC
  Peer
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
- David J. Maron, MD
  Peer
0.75 program credits
Staging Coronary Risk: A New TRANSFORMative Approach
MinuteCE®
Staging Coronary Risk: A New TRANSFORMative Approach
- Matthew Jay Budoff, MD
  Peer
0.75 program credits
MinuteCE®
TRANSFORMing Cardiovascular Care
- Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
  Peer
- Marc P. Bonaca, MD, MPH
  Peer
- Matthew Jay Budoff, MD
  Peer
- David J. Maron, MD
  Peer
- Pam R. Taub, MD, FACC, FASPC
  Peer
0.75 credits 5 episodes
Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time
MinuteCE®
Combination Therapies: Approaches for Getting to Goal Quickly vs Titration Over Time
- Marc P. Bonaca, MD, MPH
  Peer
0.75 program credits
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
MinuteCE®
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
- Naim Alkhouri, MD, FAASLD, DABOM
  Peer
- Tessa Janovsky, PA-C
  Peer
1.00 program credits
M3: Managing the Cardiometabolic Risk in MASH
MinuteCE®
M3: Managing the Cardiometabolic Risk in MASH
- Robert H. Eckel, MD, FAHA, FACC, FNLA
  Peer
- Naim Alkhouri, MD, FAASLD, DABOM
  Peer
1.00 program credits
It All Starts With a Patient
MinuteCE®
It All Starts With a Patient
- Jeff McIntyre
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended